Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups.

"Declarations Conflict of interestJAS has received personal fees from Bayer, Bellus Healthcare, Boehringer Ingelheim, GlaxoSmithKline, Menlo, NeRRe Pharmaceuticals, and Shionogi; nonfinancial support from Vitalograph; grant support and personal fees related to the submitted work from Afferent Pharmaceuticals/Merck & Co., Inc.; and grant support from Bayer, Bellus, GlaxoSmithKline, Menlo, and NeRRe Pharmaceuticals. The VitaloJAK algorithm is owned by Manchester University NHS Foundation Trust (MFT) and licensed to Vitalograph Ltd; MFT receives royalties from Vitalograph that may be shared with the department in which JAS works. JAS is also funded by the NIHR Manchester Biomedical Research Centre and a Wellcome Investigator Award and is an NIHR Senior Investigator. SSB has received advisory board/consultancy fees from Bayer, Menlo, Merck & Co., Inc., Patara, Pfizer, and Sanofi; speaker fees from Roche; and grant support from Boehringer Ingelheim and Merck & Co., Inc. PVD has received advisory board/consultancy fees from Bayer HealthCare Pharmaceuticals, Bellus Health Inc, Chiesi, Merck & Co., Inc., and Shionogi. PVD is editor-in-chief of Lung. LPM has received advisory board/consultancy fees from Applied Clinical Intelligence, Bayer, Bellus Health, Bionorica, Chiesi, Merck & Co., Inc., Nocion Therapeutics, and Shionogi. AHM has received consulting fees from Bayer, Bellus, Boehringer Ingelheim, Merck & Co., Inc., Pfizer, Proctor & Gamble, and Shionogi; lecture fees from AstraZeneca and Boehringer Ingelheim; and grant support from Afferent, Infirst, Merck & Co., Inc., and Proctor & Gamble. IDP has received personal fees from Aerocrine, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Genentech, GlaxoSmithKline, Knopp, Novartis, Regeneron, Sanofi, and Teva; and grant support from NIHR. IS has received personal fees from educational talks for general practitioners from AstraZeneca and GlaxoSmithKline; grants and personal fees from Merck Canada; consulting fees from Genentech; a European Respiratory Society Respire 3 Marie Curie Fellowship; and an E.J. Moran Campbell Early Career Award from the Department of Medicine, McMaster University (outside the submitted work). SG, BI, CLR, QL, AMN, JS, and DM are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ USA, who may own stock and/or hold stock options in the Company. Ethical ApprovalThe COUGH-1/COUGH-2 trials were performed in accordance with applicable federal regulations. All sites received approval from institutional review boards or independent ethics committees. Consent to ParticipateFor the COUGH-1/COUGH-2 trials, all patients provided written informed consent before enrollment. Consent for PublicationNot applicable. Conflict of interest JAS has received personal fees from Bayer, Bellus Healthcare, Boehringer Ingelheim, GlaxoSmithKline, Menlo, NeRRe Pharmaceuticals, and Shionogi; nonfinancial support from Vitalograph; grant support and personal fees related to the submitted work from Afferent Pharmaceuticals/Merck & Co., Inc.; and grant support from Bayer, Bellus, GlaxoSmithKline, Menlo, and NeRRe Pharmaceuticals. The VitaloJAK algorithm is owned by Manchester University NHS Foundation Trust (MFT) and licensed to Vitalograph Ltd; MFT receives royalties from Vitalograph that may be shared with the department in which JAS works. JAS is also funded by the NIHR Manchester Biomedical Research Centre and a Wellcome Investigator Award and is an NIHR Senior Investigator. SSB has received advisory board/consultancy fees from Bayer, Menlo, Merck & Co., Inc., Patara, Pfizer, and Sanofi; speaker fees from Roche; and grant support from Boehringer Ingelheim and Merck & Co., Inc. PVD has received advisory board/consultancy fees from Bayer HealthCare Pharmaceuticals, Bellus Health Inc, Chiesi, Merck & Co., Inc., and Shionogi. PVD is editor-in-chief of Lung. LPM has received advisory board/consultancy fees from Applied Clinical Intelligence, Bayer, Bellus Health, Bionorica, Chiesi, Merck & Co., Inc., Nocion Therapeutics, and Shionogi. AHM has received consulting fees from Bayer, Bellus, Boehringer Ingelheim, Merck & Co., Inc., Pfizer, Proctor & Gamble, and Shionogi; lecture fees from AstraZeneca and Boehringer Ingelheim; and grant support from Afferent, Infirst, Merck & Co., Inc., and Proctor & Gamble. IDP has received personal fees from Aerocrine, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Genentech, GlaxoSmithKline, Knopp, Novartis, Regeneron, Sanofi, and Teva; and grant support from NIHR. IS has received personal fees from educational talks for general practitioners from AstraZeneca and GlaxoSmithKline; grants and personal fees from Merck Canada; consulting fees from Genentech; a European Respiratory Society Respire 3 Marie Curie Fellowship; and an E.J. Moran Campbell Early Career Award from the Department of Medicine, McMaster University (outside the submitted work). SG, BI, CLR, QL, AMN, JS, and DM are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ USA, who may own stock and/or hold stock options in the Company."

"Funding This study, including the analysis and manuscript writing/editorial assistance, was supported by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA."